KANSAS CITY, Kan. and BOSTON, Oct. 24, 2013 /PRNewswire/ -- Aratana Therapeutics (NASDAQ: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it has appointed John Paolucci as the Company's new Director of Marketing. Mr. Paolucci brings a unique mix of human and animal health marketing experience to Aratana, including more than 15 years at Novartis Animal Health where he was responsible for launching several leading animal health products.
Julia Stephanus, Chief Commercial Officer of Aratana Therapeutics, stated, "John will play a key role in establishing marketing strategies that will turn our newly expanded pipeline into premier veterinary brands. As Aratana accelerates toward commercialization of our lead biologic and small molecule pet therapeutics, John will prepare the market for the launch of first-in-class or best-in-class products that will improve the quality of life of our pets."
Most recently, Mr. Paolucci served as Covidien's Global Marketing Director responsible for Vascular Therapies, where he managed pre-launch activities for new products and led key opinion leader development. Previously, Mr. Paolucci held the role of Director of Marketing at Navilyst Medical, formerly Boston Scientific, where he performed a key role in the expansion of the company's global presence. Mr. Paolucci launched 13 domestic and international products in his career, including five pet therapeutic products at Novartis Animal health, and he has managed numerous sales teams. Mr. Paolucci received a BS from the Colorado School of Mines, and an MA and MBA from the University of Texas.
About Aratana TherapeuticsAratana Therapeutics is a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com. Forward-Looking Statements Disclaimer This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the expansion of our commercial infrastructure; expectations regarding development programs, trials, studies, and approval; expectations regarding in-license initiatives; and expectations regarding the Company's plans and opportunities.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV